^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs
    Cancer:Non Small Cell Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Oncol Case Rep
    Title:

    Cetuximab Responsiveness in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations

    Published date:
    01/10/2022
    Excerpt:
    Next Generation Sequencing (NGS) of lung cancer tissue...showed EGFR exon 20 insertion...NGS of blood-derived circulating tumor DNA...NRAS G13V, NF1 R69fs, NF1 S340fs....The patient was started on cetuximab for EGFR exon 20 insertion and trametinib for NRAS and NF1 mutations. She was on therapy for 13 months with a partial response (Figure 1).
    Secondary therapy:
    Chemotherapy
    DOI:
    10.4172/cocr.5(1).210